Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Camtek
CAMT
$7.72B
| $5.12M | 0.01% |
1,059,300
+42,700
| +4% | +$207K |
|
1702
Q2 Holdings
QTWO
$4.04B
| $5.1M | 0.01% |
138,100
+62,100
| +82% | +$2.36M |
|
1703
Sensient Technologies
SXT
$5.68B
| $5.08M | 0.01% |
63,107
-12,453
| -16% | -$1.01M |
|
1704
CNB Financial Corp
CCNE
$1.03B
| $5.07M | 0.01% |
211,300
-18,108
| -8% | -$421K |
|
|
PAY
1705
DELISTED
Verifone Systems Inc
PAY
| $5.06M | 0.01% |
+279,319
| New | +$5.03M |
|
|
RNWK
1706
DELISTED
RealNetworks Inc
RNWK
| $5.04M | 0.01% |
1,164,623
-13,055
| -1% | -$57.1K |
|
1707
Clarus
CLAR
$140M
| $5.04M | 0.01% |
761,269
+238,757
| +46% | +$1.4M |
|
1708
Data I/O
DAIO
$32.4M
| $5.04M | 0.01% |
633,800
+169,500
| +37% | +$1.13M |
|
|
MIXT
1709
DELISTED
MIX TELEMATICS LIMITED
MIXT
| $5.04M | 0.01% |
639,100
+95,590
| +18% | +$636K |
|
1710
Aviat Networks
AVNW
$287M
| $5.04M | 0.01% |
578,766
+59,800
| +12% | +$524K |
|
|
NWLI
1711
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $5.02M | 0.01% |
15,700
+14,600
| +1,327% | +$4.55M |
|
|
PEGI
1712
DELISTED
Pattern Energy Group Inc. Class A
PEGI
| $5.02M | 0.01% |
210,400
-48,800
| -19% | -$1.09M |
|
|
FOE
1713
DELISTED
Ferro Corporation
FOE
| $5.01M | 0.01% |
274,100
+220,300
| +409% | +$3.77M |
|
1714
Magnachip Semiconductor
MX
$139M
| $5.01M | 0.01% |
511,442
+100,311
| +24% | +$898K |
|
1715
inTEST
INTT
$179M
| $5.01M | 0.01% |
753,200
+164,500
| +28% | +$1.2M |
|
|
MRLN
1716
DELISTED
Marlin Business Services Corp
MRLN
| $4.99M | 0.01% |
198,200
+18,000
| +10% | +$452K |
|
1717
Natera
NTRA
$44.7B
| $4.98M | 0.01% |
458,900
+47,500
| +12% | +$464K |
|
1718
StealthGas
GASS
$352M
| $4.98M | 0.01% |
1,532,200
+27,581
| +2% | +$92K |
|
1719
Range Resources
RRC
$9.42B
| $4.98M | 0.01% |
+214,891
| New | +$5.42M |
|
|
AMBR
1720
DELISTED
Amber Road Inc
AMBR
| $4.97M | 0.01% |
579,605
-10,895
| -2% | -$84.9K |
|
|
KS
1721
DELISTED
KapStone Paper and Pack Corp.
KS
| $4.96M | 0.01% |
+240,676
| New | +$5.18M |
|
1722
AptarGroup
ATR
$8.4B
| $4.96M | 0.01% |
57,100
-177,000
| -76% | -$14.6M |
|
|
LAND
1723
Gladstone Land Corp
LAND
$358M
| $4.95M | 0.01% |
424,397
-21,303
| -5% | -$239K |
|
1724
Bruker
BRKR
$8.79B
| $4.92M | 0.01% |
170,710
+111,600
| +189% | +$2.87M |
|
1725
Gencor Industries
GENC
$264M
| $4.92M | 0.01% |
303,900
-5,400
| -2% | -$86.4K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.